e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Tuberculosis and non-TB mycobacterial infection II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis
E. Zhukova (Novosibirsk, Russian Federation), E. Myshkova (Novosibirsk, Russian Federation)
Source:
International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Session:
Tuberculosis and non-TB mycobacterial infection II
Session type:
Thematic Poster
Number:
4638
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Zhukova (Novosibirsk, Russian Federation), E. Myshkova (Novosibirsk, Russian Federation). The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis. 4638
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017
Year: 2017
The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis
Source: Eur Respir J 2016; 48: 963-971
Year: 2016
Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources
Source: Eur Respir J 2006; 28: Suppl. 50, 28s
Year: 2006
Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006
Use of molecular-genetic methods in diagnostics and therapy of a tuberculosis (TB) at patients with HIV
Source: Annual Congress 2010 - Tuberculosis in special populations
Year: 2010
Experience of isofon use for therapy and chemoprophylaxis of tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 486s
Year: 2004
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study
Source: Eur Respir J 2015; 46: 567-570
Year: 2015
The clinical and bacteriological basis for initiating a specific treatment
Source: Annual Congress 2006 - PG11 - Clinical highlights on tuberculosis
Year: 2006
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
Source: Eur Respir J 2009; 33: 871-881
Year: 2009
Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 670-672
Year: 2016
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020
Year: 2022
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence
Source: Eur Respir J 2001; 18: Suppl. 33, 468s
Year: 2001
Immunological response in HIV-associated tuberculosis and the implications of HIV in the search for a tuberculosis vaccine
Source: Annual Congress 2007 - Tuberculosis control and HIV in Europe: good or bad news?
Year: 2007
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Source: Eur Respir J 2011; 38: 516-528
Year: 2011
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Source: Eur Respir J 2012; 39: 626-634
Year: 2012
A new era for treatment of drug-resistant tuberculosis
Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018
Year: 2018
Prevalence of inappropriate tuberculosis treatment regimens: a systematic review
Source: Eur Respir J 2012; 39: 1012-1020
Year: 2012
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Source: Eur Respir J 2012; 40: 1430-1442
Year: 2012
Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants
Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept